Mammalian target of rapamycin and head and neck squamous cell carcinoma

Head & Neck Oncology

Table 1 Clinical study for mTOR inhibitor in treatment of HNSCC

Drug	Study phase	Treatment design	Disease status	Clinicaltrial.gov identifier
Rapamycin	I/II	Neoadjuvant with 21-day rapamycin followed by surgery	Stage III or IVA, resectable	NCT01195922
Temsirolimus	II	Temsirolimus with or without cetuximab	Recurrent or metastasis	NCT01256385
	II	Temsirolimus alone	Recurrent or metastasis	NCT01172769
	I/II	Temsirolimus + Weekly paclitaxel + carboplatin	Recurrent or metastasis	NCT01016769
	I/II	Temsirolimus, cisplatin, and cetuximab	Recurrent or metastasis	NCT01015664
	II	Temsirolimus and erlotinib	Platinum-refractory or -ineligible, advanced disease	NCT01009203
Everolimus	I	Everolimus, weekly cisplatin and XRT	Locally advanced	NCT01058408
	I	Induction with everolimus, docetaxel, and cisplatin	Locally advanced	NCT00935961
	I	Everolimus, weekly cisplatin and XRT	Locally advanced	NCT00858663
	I	Everolimus, cisplatin and XRT	Locally advanced	NCT01057277
	I/II	Induction everolimus paclitaxel, and cisplatin	Locally advanced	NCT01133678
	II, randomized	Adjuvant everolimus Vs placebo	Locally advanced disease after definite local treatment	NCT01111058
	I/IIB	Everolimus, carboplatin, and cetuximab	Recurrent or metastaasis	NCT01283334
	I/II	Everolimus, cetuximab and cisplatin	Recurrent or metastaasis	NCT01009346
	II	Everolimus	Refractory, recurrent or metastasis	NCT01051791
	II	Everolimus, erlotinib	Recurrent	NCT00942734
Ridaforolimus	I	Ridaforolimus, cetuximab	Advanced	NCT01212627